Evidence map›Paper›PMID 23350875›Full record

ArticleBMC genomics2013

A colorectal cancer genome-wide association study in a Spanish cohort identifies two variants associated with colorectal cancer risk at 1p33 and 8p12.

Ceres Fernandez-Rozadilla, Jean-Baptiste Cazier, Ian P Tomlinson, Luis G Carvajal-Carmona, Claire Palles, María J Lamas, Montserrat Baiget, Luis A López-Fernández, Alejandro Brea-Fernández, Anna Abulí and 14 more

Open access · goldAbstract read
In one paragraph

Article in BMC genomics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Evaluating the Potential of Polygenic Risk Score to Improve Colorectal Cancer Screening.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022
    Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Observational
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 12 institutions in 3 countries.

Ceres Fernandez-RozadillaGalician Public Fundation of Genomic Medicine (FPGMX)-Grupo de Medicina Xenómica-Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERer)-IDIS, Santiago de Compostela, 15706, Spain.
Jean-Baptiste Cazier
Ian P Tomlinson
Luis G Carvajal-Carmona
Claire Palles
María J Lamas
Montserrat Baiget
Luis A López-Fernández
Alejandro Brea-Fernández
Anna Abulí
Luis Bujanda
Juan Clofent
Dolors Gonzalez
Rosa Xicola
Montserrat Andreu
Xavier Bessa
Rodrigo Jover
Xavier Llor
EPICOLON Consortium
Víctor Moreno
Antoni Castells
Ángel Carracedo
Sergi Castellvi-Bel
Clara Ruiz-Ponte
Fundación Pública Galega de Medicina Xenómica · ESCentre for Biomedical Network Research on Rare Diseases · ESCentre for Human Genetics · GBConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESHospital Del Mar · ESHospital de Sant Pau · ESHospital General Universitario Gregorio Marañón · ESInstitut Català d'Oncologia · ESUniversitat de Barcelona · ESUniversity of California, Davis · USUniversity of Illinois Chicago · USUniversity of Oxford · GB

Funding

Cancer Research UK 16459Wellcome Trust 075491/Z/04Wellcome Trust 076113Wellcome Trust 085475Wellcome Trust 090532
6 · The paper itself

Abstract

backgroundColorectal cancer (CRC) is a disease of complex aetiology, with much of the expected inherited risk being due to several common low risk variants. Genome-Wide Association Studies (GWAS) have identified 20 CRC risk variants. Nevertheless, these have only been able to explain part of the missing heritability. Moreover, these signals have only been inspected in populations of Northern European origin.

resultsThus, we followed the same approach in a Spanish cohort of 881 cases and 667 controls. Sixty-four variants at 24 loci were found to be associated with CRC at p-values <10-5. We therefore evaluated the 24 loci in another Spanish replication cohort (1481 cases and 1850 controls). Two of these SNPs, rs12080929 at 1p33 (Preplication=0.042; Ppooled=5.523x10-03; OR (CI95%)=0.866(0.782-0.959)) and rs11987193 at 8p12 (Preplication=0.039; Ppooled=6.985x10-5; OR (CI95%)=0.786(0.705-0.878)) were replicated in the second Phase, although they did not reach genome-wide statistical significance.

conclusionsWe have performed the first CRC GWAS in a Southern European population and by these means we were able to identify two new susceptibility variants at 1p33 and 8p12 loci. These two SNPs are located near the SLC5A9 and DUSP4 loci, respectively, which could be good functional candidates for the association signals. We therefore believe that these two markers constitute good candidates for CRC susceptibility loci and should be further evaluated in other larger datasets. Moreover, we highlight that were these two SNPs true susceptibility variants, they would constitute a decrease in the CRC missing heritability fraction.

Indexed as

Genome, HumanGenome-Wide Association StudyAgedAged, 80 and overChromosomes, Human, Pair 1Chromosomes, Human, Pair 8Cohort StudiesColorectal NeoplasmsDual-Specificity PhosphatasesFemaleGenetic LociGenotypeHumansMaleMiddle AgedMitogen-Activated Protein Kinase PhosphatasesDual-Specificity PhosphatasesDUSP4 protein, humanMitogen-Activated Protein Kinase Phosphatases

Identifiers

PMID23350875
PMCPMC3616862
OpenAlexW2040056194

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.